Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Moore

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
European Journal of Gastroenterology & Hepatology|November 2, 2012
A multicentre study to determine the incidence, demographics, aetiology and outcomes of 6-day emergency readmission following day-case endoscopySanchoy Sarkar, Joe Geraghty, Andrew R Moore, et al.
Journal of Functional Morphology and Kinesiology|May 23, 2025
Relationship Between Systemic Inflammation and Glycemic Control in FirefightersTiffany J Oberther, Andrew R Moore, Austin A Kohler, et al.
BMC Musculoskeletal Disorders|July 20, 2011
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitisPaul M Peloso, Arnold Gammaitoni, Steven S Smugar, et al.
Current Oncology Reports|January 21, 2022
New Developments in Gastric Neuroendocrine NeoplasmsKlaire Exarchou, Nathan A Stephens, Andrew R Moore, et al.
Muscles (Basel, Switzerland)|August 4, 2025
Discrepancy of Beta-Hydroxybutyrate Measurements between a Blood Meter and GC-MS Methods in Healthy HumansAngelia Maleah Holland-Winkler, Andrew R Moore, Jenna K Ansley, et al.
Plos One|October 8, 2013
Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritisAndrew R Moore, Malcolm Boyce, Islay A Steele, et al.
Pain|March 30, 2010
Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gainAndrew R Moore, Sebastian Straube, Jocelyn Paine, et al.
Neuroendocrinology|September 16, 2020
A "Watch and Wait" Strategy Involving Regular Endoscopic Surveillance Is Safe for Many Patients with Small, Sporadic, Grade 1, Non-Ampullary, Non-Functioning Duodenal Neuroendocrine TumoursKlaire Exarchou, Andrew R Moore, Howard L Smart, et al.
Pain|July 15, 2010
"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviewsAndrew R Moore, Christopher Eccleston, Sheena Derry, et al.
Sports Medicine and Health Science|September 23, 2024
Music alters heart rate and psychological responses but not muscle activation during light-intensity isometric exerciseAndrew R Moore, Jasmin C Hutchinson, Christa Winter, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
European Journal of Gastroenterology & Hepatology|November 2, 2012
A multicentre study to determine the incidence, demographics, aetiology and outcomes of 6-day emergency readmission following day-case endoscopySanchoy Sarkar, Joe Geraghty, Andrew R Moore, et al.
Journal of Functional Morphology and Kinesiology|May 23, 2025
Relationship Between Systemic Inflammation and Glycemic Control in FirefightersTiffany J Oberther, Andrew R Moore, Austin A Kohler, et al.
BMC Musculoskeletal Disorders|July 20, 2011
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitisPaul M Peloso, Arnold Gammaitoni, Steven S Smugar, et al.
Current Oncology Reports|January 21, 2022
New Developments in Gastric Neuroendocrine NeoplasmsKlaire Exarchou, Nathan A Stephens, Andrew R Moore, et al.
Muscles (Basel, Switzerland)|August 4, 2025
Discrepancy of Beta-Hydroxybutyrate Measurements between a Blood Meter and GC-MS Methods in Healthy HumansAngelia Maleah Holland-Winkler, Andrew R Moore, Jenna K Ansley, et al.
Plos One|October 8, 2013
Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritisAndrew R Moore, Malcolm Boyce, Islay A Steele, et al.
Pain|March 30, 2010
Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gainAndrew R Moore, Sebastian Straube, Jocelyn Paine, et al.
Neuroendocrinology|September 16, 2020
A "Watch and Wait" Strategy Involving Regular Endoscopic Surveillance Is Safe for Many Patients with Small, Sporadic, Grade 1, Non-Ampullary, Non-Functioning Duodenal Neuroendocrine TumoursKlaire Exarchou, Andrew R Moore, Howard L Smart, et al.
Pain|July 15, 2010
"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviewsAndrew R Moore, Christopher Eccleston, Sheena Derry, et al.
Sports Medicine and Health Science|September 23, 2024
Music alters heart rate and psychological responses but not muscle activation during light-intensity isometric exerciseAndrew R Moore, Jasmin C Hutchinson, Christa Winter, et al.
Pageof 7